hydrogen carbonate has been researched along with Disease Exacerbation in 61 studies
Bicarbonates: Inorganic salts that contain the -HCO3 radical. They are an important factor in determining the pH of the blood and the concentration of bicarbonate ions is regulated by the kidney. Levels in the blood are an index of the alkali reserve or buffering capacity.
hydrogencarbonate : The carbon oxoanion resulting from the removal of a proton from carbonic acid.
| Excerpt | Relevance | Reference |
|---|---|---|
| " In many cases of pediatric ethylene glycol poisoning treated with fomepizole, hemodialysis may not be necessary despite high concentrations and the presence of metabolic acidosis." | 4.86 | Fomepizole for the treatment of pediatric ethylene and diethylene glycol, butoxyethanol, and methanol poisonings. ( Brent, J, 2010) |
| "Whether treating metabolic acidosis slows progression of chronic kidney disease (CKD) has not been established." | 3.30 | Design and population of the VALOR-CKD study: a multicenter, randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of veverimer in slowing progression of chronic kidney disease in patients with metabolic acidosis. ( Bushinsky, DA; Inker, L; Klaerner, G; Li, E; Mathur, VS; Parsell, D; Perkovic, V; Stasiv, Y; Tangri, N; Walker, M; Wesson, DE; Wheeler, DC, 2023) |
| "2,628 adults with type 2 diabetes and nephropathy." | 2.80 | Serum Bicarbonate and Kidney Disease Progression and Cardiovascular Outcome in Patients With Diabetic Nephropathy: A Post Hoc Analysis of the RENAAL (Reduction of End Points in Non-Insulin-Dependent Diabetes With the Angiotensin II Antagonist Losartan) St ( Bakker, SJ; de Zeeuw, D; Gansevoort, RT; Lambers Heerspink, HJ; Lewis, JB; Lutgers, HL; Schutte, E; Umanath, K; Vart, P; Wolffenbuttel, BH, 2015) |
| "Although hyperkalemia is a well-recognized complication of CKD, the prevalence rates of hyperkalemia (14%-20%) and hypokalemia (12%-18%) are similar." | 2.55 | Hyperkalemia and Hypokalemia in CKD: Prevalence, Risk Factors, and Clinical Outcomes. ( Gilligan, S; Raphael, KL, 2017) |
| "Metabolic acidosis is a common complication associated with progressive loss of kidney function." | 2.48 | Metabolic acidosis and kidney disease: does bicarbonate therapy slow the progression of CKD? ( Kovesdy, CP, 2012) |
| "Although metabolic acidosis is known as a potential complication of chronic kidney disease (CKD), there is limited information concerning the association between metabolic acidosis and clinical outcomes." | 1.72 | Lower bicarbonate level is associated with CKD progression and all-cause mortality: a propensity score matching analysis. ( Fukasawa, H; Furuya, R; Kaneko, M; Uchiyama, Y; Yasuda, H, 2022) |
| "Patients with ADPKD from the DIPAK (Developing Interventions to halt Progression of ADPKD) trial were included [n = 296, estimated glomerular filtration rate (eGFR) 50 ± 11 mL/min/1." | 1.62 | Serum bicarbonate is associated with kidney outcomes in autosomal dominant polycystic kidney disease. ( Blijdorp, CJ; Gansevoort, RT; Hoorn, EJ; Musterd-Bhaggoe, UM; Severs, D; Zietse, R, 2021) |
| "Both high and low pre-ESRD CO2 levels (≥28 and <18 mEq/L) during 6 months prior to dialysis transition and rate of CO2 decline >4 mEq/L/year during 1 year before dialysis initiation were associated with greater post-ESRD all-cause, CV, and non-CV mortality." | 1.62 | Association of Pre-ESRD Serum Bicarbonate with Post-ESRD Mortality in Patients with Incident ESRD. ( Catabay, CJ; Hsiung, JT; Kalantar-Zadeh, K; Kleine, CE; Kovesdy, CP; Kraut, J; Lee, Y; Murray, V; Obi, Y; Park, C; Rhee, CM; Soohoo, M; Streja, E; Tantisattamo, E; Wenziger, C, 2021) |
| "Metabolic acidosis is commonly found in patients with chronic kidney disease (CKD), and its causes are: impaired ammonia excretion, reduced tubular bicarbonate reabsorption and insufficient renal bicarbonate production in relation to the amount of acids synthesised by the body and ingested with food." | 1.48 | Diagnosis and Treatment of Metabolic Acidosis in Patients with Chronic Kidney Disease - Position Statement of the Working Group of the Polish Society of Nephrology. ( Adamczak, M; Madziarska, K; Masajtis-Zagajewska, A; Mazanowska, O; Stompór, T; Więcek, A, 2018) |
| "Lactic acidosis is the result of imbalance between the systemic formation of lactate and its hepatic metabolism." | 1.40 | Warburg's effect on solid tumors. ( El Imad, T; El Khoury, L; Geara, AS, 2014) |
| "Kidney disease progression was defined as either a decrease in estimated glomerular filtration rate (eGFR) by 50% or reaching an eGFR less than 15 mL/min/1." | 1.35 | Serum bicarbonate levels and the progression of kidney disease: a cohort study. ( Abramowitz, M; Hostetter, TH; Melamed, ML; Shah, SN, 2009) |
| "Metabolic acidosis is a consequence of chronic renal failure and it may produce bone demineralization, muscle proteolysis, and progression of chronic renal failure." | 1.32 | Calcium citrate ameliorates the progression of chronic renal injury. ( Boggia, J; Ferreiro, A; Gadola, L; García, S; Márquez, MN; Musto, ML; Nin, N; Noboa, O; Ortega, V; Pizarrosa, C; Ponte, P; Ravaglio, S; Rodriguez, MJ; Sesser, P; Vallega, A, 2004) |
| "Acute pancreatitis was induced in 40 Sprague-Dawley rats by ligation of the main biliopancreatic duct." | 1.31 | Whole gut washout ameliorates the progression of acute experimental pancreatitis. ( Aksoy, F; Ozer, S; Vatansev, C; Yol, S, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (1.64) | 18.2507 |
| 2000's | 9 (14.75) | 29.6817 |
| 2010's | 38 (62.30) | 24.3611 |
| 2020's | 13 (21.31) | 2.80 |
| Authors | Studies |
|---|---|
| Fukasawa, H | 1 |
| Kaneko, M | 1 |
| Uchiyama, Y | 1 |
| Yasuda, H | 1 |
| Furuya, R | 1 |
| Ahmad, H | 1 |
| Wertin, T | 1 |
| Zhang, Y | 2 |
| Neher, JO | 1 |
| Auten, B | 1 |
| Brown, DD | 2 |
| Carroll, M | 1 |
| Ng, DK | 2 |
| Levy, RV | 1 |
| Greenbaum, LA | 1 |
| Kaskel, FJ | 2 |
| Furth, SL | 2 |
| Warady, BA | 2 |
| Melamed, ML | 4 |
| Dauber, A | 1 |
| Mathur, VS | 1 |
| Bushinsky, DA | 1 |
| Inker, L | 1 |
| Klaerner, G | 1 |
| Li, E | 1 |
| Parsell, D | 1 |
| Perkovic, V | 1 |
| Stasiv, Y | 1 |
| Walker, M | 1 |
| Wesson, DE | 2 |
| Wheeler, DC | 1 |
| Tangri, N | 2 |
| Woodman, R | 1 |
| Miller, C | 1 |
| Student, J | 1 |
| Freeman, K | 1 |
| Perl, D | 1 |
| Lockette, W | 1 |
| El-Kenawi, A | 1 |
| Gatenbee, C | 1 |
| Robertson-Tessi, M | 1 |
| Bravo, R | 1 |
| Dhillon, J | 1 |
| Balagurunathan, Y | 1 |
| Berglund, A | 1 |
| Vishvakarma, N | 1 |
| Ibrahim-Hashim, A | 1 |
| Choi, J | 1 |
| Luddy, K | 1 |
| Gatenby, R | 1 |
| Pilon-Thomas, S | 1 |
| Anderson, A | 1 |
| Ruffell, B | 1 |
| Gillies, R | 1 |
| Wiegand, A | 1 |
| Graf, N | 1 |
| Bonani, M | 1 |
| Frey, D | 1 |
| Wüthrich, RP | 1 |
| Mohebbi, N | 1 |
| Horwitz, EJ | 1 |
| Dobre, MA | 1 |
| Abramowitz, MK | 3 |
| Zhang, L | 1 |
| Lo, Y | 1 |
| Mitch, WE | 1 |
| Hostetter, TH | 2 |
| Roem, J | 1 |
| Reidy, KJ | 1 |
| Kumar, J | 1 |
| Mak, RH | 1 |
| Schwartz, GJ | 1 |
| Madias, NE | 2 |
| Kajimoto, S | 1 |
| Sakaguchi, Y | 1 |
| Asahina, Y | 1 |
| Kaimori, JY | 1 |
| Isaka, Y | 1 |
| Blijdorp, CJ | 1 |
| Severs, D | 1 |
| Musterd-Bhaggoe, UM | 1 |
| Gansevoort, RT | 2 |
| Zietse, R | 1 |
| Hoorn, EJ | 1 |
| Tantisattamo, E | 1 |
| Murray, V | 1 |
| Obi, Y | 1 |
| Park, C | 1 |
| Catabay, CJ | 1 |
| Lee, Y | 1 |
| Wenziger, C | 1 |
| Hsiung, JT | 1 |
| Soohoo, M | 1 |
| Kleine, CE | 1 |
| Rhee, CM | 1 |
| Kraut, J | 1 |
| Kovesdy, CP | 2 |
| Kalantar-Zadeh, K | 1 |
| Streja, E | 1 |
| Hultin, S | 1 |
| Johnson, DW | 1 |
| Badve, SV | 1 |
| Reaven, NL | 1 |
| Funk, SE | 1 |
| Ferguson, TW | 1 |
| Collister, D | 1 |
| Mathur, V | 1 |
| Harambat, J | 1 |
| Kunzmann, K | 1 |
| Azukaitis, K | 1 |
| Bayazit, AK | 1 |
| Canpolat, N | 1 |
| Doyon, A | 1 |
| Duzova, A | 1 |
| Niemirska, A | 1 |
| Sözeri, B | 1 |
| Thurn-Valsassina, D | 1 |
| Anarat, A | 1 |
| Bessenay, L | 1 |
| Candan, C | 1 |
| Peco-Antic, A | 1 |
| Yilmaz, A | 1 |
| Tschumi, S | 1 |
| Testa, S | 1 |
| Jankauskiene, A | 1 |
| Erdogan, H | 1 |
| Rosales, A | 1 |
| Alpay, H | 1 |
| Lugani, F | 1 |
| Arbeiter, K | 1 |
| Mencarelli, F | 1 |
| Kiyak, A | 1 |
| Dönmez, O | 1 |
| Drozdz, D | 1 |
| Melk, A | 1 |
| Querfeld, U | 1 |
| Schaefer, F | 1 |
| Chen, W | 1 |
| Gilligan, S | 1 |
| Raphael, KL | 3 |
| Adamczak, M | 1 |
| Masajtis-Zagajewska, A | 1 |
| Mazanowska, O | 1 |
| Madziarska, K | 1 |
| Stompór, T | 1 |
| Więcek, A | 1 |
| Li, S | 1 |
| Wang, YY | 1 |
| Cui, J | 1 |
| Chen, DN | 1 |
| Li, Y | 1 |
| Xin, Z | 1 |
| Xie, RR | 1 |
| Cao, X | 1 |
| Lu, J | 1 |
| Yang, FY | 1 |
| Yang, JK | 1 |
| Maruta, Y | 1 |
| Hasegawa, T | 1 |
| Yamakoshi, E | 1 |
| Nishiwaki, H | 1 |
| Koiwa, F | 1 |
| Imai, E | 1 |
| Hishida, A | 1 |
| Banerjee, T | 1 |
| Crews, DC | 1 |
| McCulloch, CE | 1 |
| Johansen, KL | 1 |
| Saydah, S | 1 |
| Rios Burrows, N | 1 |
| Saran, R | 1 |
| Gillespie, B | 1 |
| Bragg-Gresham, J | 1 |
| Powe, NR | 1 |
| Dobre, M | 3 |
| Yang, W | 2 |
| Chen, J | 3 |
| Drawz, P | 1 |
| Hamm, LL | 2 |
| Horwitz, E | 1 |
| Hostetter, T | 2 |
| Jaar, B | 1 |
| Lora, CM | 1 |
| Nessel, L | 1 |
| Ojo, A | 1 |
| Scialla, J | 1 |
| Steigerwalt, S | 1 |
| Teal, V | 1 |
| Wolf, M | 3 |
| Rahman, M | 2 |
| Checheriţă, IA | 1 |
| David, C | 1 |
| Ciocâlteu, A | 1 |
| Lascăr, I | 1 |
| Budală, L | 1 |
| Kanda, E | 1 |
| Ai, M | 1 |
| Kuriyama, R | 1 |
| Yoshida, M | 1 |
| Shiigai, T | 1 |
| Goldenstein, L | 2 |
| Driver, TH | 2 |
| Fried, LF | 2 |
| Rifkin, DE | 1 |
| Patel, KV | 1 |
| Yenchek, RH | 1 |
| Harris, TB | 1 |
| Kritchevsky, SB | 1 |
| Newman, AB | 1 |
| Sarnak, MJ | 3 |
| Shlipak, MG | 2 |
| Ix, JH | 2 |
| Katz, R | 1 |
| Hoofnagle, AN | 1 |
| Siscovick, DS | 1 |
| Kestenbaum, B | 1 |
| de Boer, IH | 1 |
| Ying, J | 1 |
| Greene, T | 3 |
| El Imad, T | 1 |
| El Khoury, L | 1 |
| Geara, AS | 1 |
| Chase, HS | 1 |
| Hirsch, JS | 1 |
| Mohan, S | 1 |
| Rao, MK | 1 |
| Radhakrishnan, J | 1 |
| Pan, Q | 1 |
| Appel, L | 1 |
| Bellovich, K | 1 |
| Feldman, H | 1 |
| Fischer, MJ | 1 |
| Ham, LL | 1 |
| Jaar, BG | 1 |
| Kallem, RR | 2 |
| Rosas, SE | 1 |
| Scialla, JJ | 2 |
| Beaubien-Souligny, W | 1 |
| Bezzaoucha, S | 1 |
| Pichette, V | 1 |
| Lafrance, JP | 1 |
| Bell, R | 1 |
| Lamarche, C | 1 |
| Ouimet, D | 1 |
| Vallee, M | 1 |
| Schutte, E | 1 |
| Lambers Heerspink, HJ | 1 |
| Lutgers, HL | 1 |
| Bakker, SJ | 1 |
| Vart, P | 1 |
| Wolffenbuttel, BH | 1 |
| Umanath, K | 1 |
| Lewis, JB | 1 |
| de Zeeuw, D | 1 |
| Kraut, JA | 1 |
| Henning, DJ | 1 |
| Oedorf, K | 1 |
| Day, DE | 1 |
| Redfield, CS | 1 |
| Huguenel, CJ | 1 |
| Roberts, JC | 1 |
| Sanchez, LD | 1 |
| Wolfe, RE | 1 |
| Shapiro, NI | 1 |
| Cooper, LB | 1 |
| Mentz, RJ | 1 |
| Gallup, D | 1 |
| Lala, A | 1 |
| DeVore, AD | 1 |
| Vader, JM | 1 |
| AbouEzzeddine, OF | 1 |
| Bart, BA | 1 |
| Anstrom, KJ | 1 |
| Hernandez, AF | 1 |
| Felker, GM | 1 |
| Pena-Polanco, JE | 1 |
| Asplin, J | 1 |
| Chang, AR | 1 |
| Lash, J | 1 |
| Hsu, CY | 1 |
| Feldman, HI | 1 |
| Appel, LJ | 1 |
| Anderson, CA | 1 |
| Havlín, J | 1 |
| Matoušovic, K | 1 |
| Vaňková, S | 1 |
| Schück, O | 1 |
| Das, S | 1 |
| Misra, B | 1 |
| Roul, L | 1 |
| Minz, NT | 1 |
| Pattnaik, M | 1 |
| Baig, MA | 1 |
| Shah, SN | 1 |
| Abramowitz, M | 1 |
| Good, DW | 1 |
| George, T | 1 |
| Watts, BA | 1 |
| Lim, BL | 1 |
| Kelly, AM | 1 |
| Brent, J | 1 |
| Menon, V | 1 |
| Tighiouart, H | 1 |
| Vaughn, NS | 1 |
| Beck, GJ | 1 |
| Kusek, JW | 1 |
| Collins, AJ | 1 |
| Wei, G | 1 |
| Baird, BC | 1 |
| Beddhu, S | 1 |
| Sahni, V | 1 |
| Rosa, RM | 1 |
| Batlle, D | 1 |
| Hegyi, P | 1 |
| Venglovecz, V | 1 |
| Pallagi, P | 1 |
| Maléth, J | 1 |
| Takács, T | 1 |
| Rakonczay, Z | 1 |
| Hulikova, A | 1 |
| Vaughan-Jones, RD | 1 |
| Swietach, P | 1 |
| Jha, R | 1 |
| Muthukrishnan, J | 1 |
| Shiradhonkar, S | 1 |
| Patro, K | 1 |
| Harikumar, K | 1 |
| Modi, KD | 1 |
| Morimoto, N | 1 |
| Deguchi, K | 1 |
| Sato, K | 1 |
| Yunoki, T | 1 |
| Deguchi, S | 1 |
| Ohta, Y | 1 |
| Kurata, T | 1 |
| Takao, Y | 1 |
| Ikeda, Y | 1 |
| Matsuura, T | 1 |
| Abe, K | 1 |
| Caravaca, F | 1 |
| Villa, J | 1 |
| García de Vinuesa, E | 1 |
| Martínez del Viejo, C | 1 |
| Martínez Gallardo, R | 1 |
| Macías, R | 1 |
| Ferreira, F | 1 |
| Cerezo, I | 1 |
| Hernández-Gallego, R | 1 |
| Pelley, JR | 1 |
| Gordon, SR | 1 |
| Gardner, TB | 1 |
| Elliott, J | 1 |
| Syme, HM | 1 |
| Markwell, PJ | 1 |
| Al-Hassnan, ZN | 1 |
| Boyadjiev, SA | 1 |
| Praphanphoj, V | 1 |
| Hamosh, A | 1 |
| Braverman, NE | 1 |
| Thomas, GH | 1 |
| Geraghty, MT | 1 |
| Gadola, L | 1 |
| Noboa, O | 1 |
| Márquez, MN | 1 |
| Rodriguez, MJ | 1 |
| Nin, N | 1 |
| Boggia, J | 1 |
| Ferreiro, A | 1 |
| García, S | 1 |
| Ortega, V | 1 |
| Musto, ML | 1 |
| Ponte, P | 1 |
| Sesser, P | 1 |
| Pizarrosa, C | 1 |
| Ravaglio, S | 1 |
| Vallega, A | 1 |
| Caravati, EM | 1 |
| Heileson, HL | 1 |
| Jones, M | 1 |
| Mazouz, H | 1 |
| Kacso, I | 1 |
| Ghazali, A | 1 |
| El Esper, N | 1 |
| Moriniere, P | 1 |
| Makdassi, R | 1 |
| Hardy, P | 1 |
| Westeel, PF | 1 |
| Achard, JM | 1 |
| Pruna, A | 1 |
| Fournier, A | 1 |
| Yol, S | 1 |
| Ozer, S | 1 |
| Aksoy, F | 1 |
| Vatansev, C | 1 |
| Urakami, T | 1 |
| Inami, I | 1 |
| Morimoto, S | 1 |
| Kubota, S | 1 |
| Owada, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Chronic Kidney Disease in Children Prospective Cohort Study (CKiD)[NCT00327860] | 1,100 participants (Actual) | Observational | 2003-10-31 | Active, not recruiting | |||
| Placebo-controlled Randomized Clinical Trial of Alkali Therapy in Patients With Chronic Kidney Disease[NCT01452412] | Phase 2/Phase 3 | 149 participants (Actual) | Interventional | 2011-10-31 | Completed | ||
| A Phase 3b, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of TRC101 in Delaying Chronic Kidney Disease Progression in Subjects With Metabolic Acidosis[NCT03710291] | Phase 3 | 1,480 participants (Actual) | Interventional | 2018-11-20 | Terminated (stopped due to Administrative reasons) | ||
| Chlortalidone and Bumetanide in Advanced Chronic Kidney Disease: HEBE-CKD Trial[NCT03923933] | Phase 2 | 34 participants (Actual) | Interventional | 2019-06-18 | Completed | ||
| Prospective Cohort Study of Chronic Renal Insufficiency[NCT00304148] | 5,499 participants (Anticipated) | Observational | 2003-07-31 | Active, not recruiting | |||
| Pilot Study of Sodium Bicarbonate in Generally Healthy People With Low Bicarbonate[NCT02743650] | 7 participants (Actual) | Interventional | 2016-02-29 | Terminated (stopped due to Difficulties identifying subjects who were qualified to participate in the study) | |||
| Sodium Bicarbonate to Treat Severe Acidosis in the Critically Ill : A Multiple Center Randomized Clinical Trial (BICAR-ICU)[NCT02476253] | Phase 3 | 400 participants (Anticipated) | Interventional | 2015-05-05 | Recruiting | ||
| Randomized Trial of Sodium Bicarbonate in Renal Transplant Recipients With Low-normal Serum Bicarbonate Levels[NCT01225796] | Early Phase 1 | 29 participants (Actual) | Interventional | 2010-11-30 | Completed | ||
| Magnetic Resonance Cholangiopancreatography (MRCP): A Reliable, Non Invasive Method for Staging Chronic Pancreatitis From Minimal Change Disease to the Advanced Stages in Pediatrics[NCT02869893] | 57 participants (Actual) | Interventional | 2016-08-10 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The investigators will evaluate changes in bone mineral density at the wrist. (NCT01452412)
Timeframe: 2 year
| Intervention | g/cm2 (Mean) |
|---|---|
| Sodium Bicarbonate | 0.75 |
| Placebo | 0.73 |
Estimated GFR (NCT01452412)
Timeframe: 2 year
| Intervention | ml/min/1.73m2 (Mean) |
|---|---|
| Sodium Bicarbonate | 38.5 |
| Placebo | 36.3 |
Hand-grip strength will be measured in all participants (NCT01452412)
Timeframe: 2 year
| Intervention | kg (Mean) |
|---|---|
| Sodium Bicarbonate | 27.3 |
| Placebo | 24.9 |
Short Form- 36 (SF-36) will be performed in all participants. We will evaluate effects on the Physical Function Domain. The Physical Function Domain is scored from 0 to 100 with higher scores meaning better physical functioning. (NCT01452412)
Timeframe: 2 year
| Intervention | score on a scale (Mean) |
|---|---|
| Sodium Bicarbonate | 40 |
| Placebo | 43 |
Sit to stand to sit x10 speed (time to perform sit to stand to sit 10 times) will be measured and compared between groups. (NCT01452412)
Timeframe: 2 year
| Intervention | seconds (Mean) |
|---|---|
| Sodium Bicarbonate | 23.8 |
| Placebo | 22.9 |
(NCT03923933)
Timeframe: Change from Basal to day 28
| Intervention | mmHg (Mean) |
|---|---|
| Placebo | -3.4 |
| Treatment Grup | -13.5 |
Decrease in extracellular water measured by bioelectrical impedance analysis (NCT03923933)
Timeframe: Change from Basal to day 28
| Intervention | litres (Mean) |
|---|---|
| Placebo | -0.15 |
| Treatment Grup | 2.55 |
Decrease in extracellular water / total body water ratio measured by bioelectrical impedance analysis (NCT03923933)
Timeframe: Change from Basal to day 28
| Intervention | percentage of ECW/TBW (Mean) |
|---|---|
| Placebo | -0.24 |
| Treatment Grup | -2.92 |
decrease in blood pressure compared wit baseline measure (mmhg) (NCT03923933)
Timeframe: Change from Basal to day 28
| Intervention | mmHg (Mean) |
|---|---|
| Placebo | -5.4 |
| Treatment Grup | -18.1 |
(NCT03923933)
Timeframe: Change from Basal to day 28
| Intervention | mmHg (Mean) |
|---|---|
| Placebo | -10 |
| Treatment Grup | -26.1 |
Increase in the fractional excretion of sodium compared with the baseline measure (NCT03923933)
Timeframe: Change from Basal to day 28
| Intervention | percentage of sodium excreted (Mean) |
|---|---|
| Placebo | -0.348 |
| Treatment Grup | 0.598 |
Measured by bioelectrical impedance analysis, compared to the initial measurement (NCT03923933)
Timeframe: Change from Basal to day 28
| Intervention | litres (Mean) |
|---|---|
| Placebo | -0.075 |
| Treatment Grup | -4.36 |
Healthy controls underwent 3D MRE on a 1.5T scanner. Regions of interest for measurement of pancreatic stiffness were drawn by two blinded readers and statistical analysis were performed for comparisons between the 2 groups. (NCT02869893)
Timeframe: Single time point, pre-secretin
| Intervention | kPa (Mean) |
|---|---|
| Healthy Participants | 1.7 |
"Participants underwent MR imaging prior to and following secretin administration. Pre-secretin imaging lasts approximately 20 minutes. Post-secretin images were acquired at 1 minute, 5 minutes and 15 minutes following completion of secretin injection. Pre-secretin enteric fluid volumes were subtracted from post-secretin enteric fluid volumes for each participant to determine volume secreted in response to secretin administration at each time point.~A commercially available software package determines the area of fluid signal on the MR images. The fluid signal from the pre-secretin images is then subtracted from the each post-secretin image (1, 5 and 15 minutes images) to determine the amount of fluid produced by the introduction of secretin." (NCT02869893)
Timeframe: 35 minutes (20 min pre-secretin, 15 minutes post-secretin)
| Intervention | mL (Median) |
|---|---|
| Healthy Participants | 79 |
Pancreatic parenchymal volume by manual segmentation (tracing) of pancreas contours on magnetic resonance imaging (MRI) (NCT02869893)
Timeframe: Single time point, pre-secretin
| Intervention | mL (Mean) |
|---|---|
| Healthy Participants | 46 |
8 reviews available for hydrogen carbonate and Disease Exacerbation
| Article | Year |
|---|---|
Recent evidence on the effect of treatment of metabolic acid on the progression of kidney disease.
Topics: Acidosis; Bicarbonates; Disease Progression; Humans; Kidney; Renal Insufficiency, Chronic | 2021 |
Epidemiology of Acid-Base Derangements in CKD.
Topics: Acid-Base Equilibrium; Acid-Base Imbalance; Bicarbonates; Disease Progression; Humans; Prevalence; R | 2017 |
Hyperkalemia and Hypokalemia in CKD: Prevalence, Risk Factors, and Clinical Outcomes.
Topics: Age Factors; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Bicarbonate | 2017 |
Metabolic Acidosis of CKD: An Update.
Topics: Acid-Base Equilibrium; Acidosis; Animals; Bicarbonates; Disease Progression; Glomerular Filtration R | 2016 |
Established and Emerging Strategies in the Treatment of Chronic Kidney Disease.
Topics: Allopurinol; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Bicarbonate | 2016 |
A meta-analysis on the utility of peripheral venous blood gas analyses in exacerbations of chronic obstructive pulmonary disease in the emergency department.
Topics: Bicarbonates; Blood Gas Analysis; Carbon Dioxide; Confidence Intervals; Disease Progression; Humans; | 2010 |
Fomepizole for the treatment of pediatric ethylene and diethylene glycol, butoxyethanol, and methanol poisonings.
Topics: Acidosis; Adult; Alcoholism; Antidotes; Bicarbonates; Child; Disease Progression; Ethanol; Ethylene | 2010 |
Metabolic acidosis and kidney disease: does bicarbonate therapy slow the progression of CKD?
Topics: Acid-Base Equilibrium; Acidosis; Bicarbonates; Clinical Trials as Topic; Disease Progression; Homeos | 2012 |
6 trials available for hydrogen carbonate and Disease Exacerbation
| Article | Year |
|---|---|
Design and population of the VALOR-CKD study: a multicenter, randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of veverimer in slowing progression of chronic kidney disease in patients with metabolic acidosis.
Topics: Acidosis; Bicarbonates; Disease Progression; Double-Blind Method; Female; Glomerular Filtration Rate | 2023 |
Effects of Sodium Bicarbonate in CKD Stages 3 and 4: A Randomized, Placebo-Controlled, Multicenter Clinical Trial.
Topics: Bicarbonates; Biomarkers; Disease Progression; Dose-Response Relationship, Drug; Female; Follow-Up S | 2020 |
Oral treatment of metabolic acidosis in hemodialyzed patients and the implications on the hemodynamic status.
Topics: Acidosis; Administration, Oral; Adult; Aged; Bicarbonates; Disease Progression; Female; Follow-Up St | 2013 |
Serum Bicarbonate and Kidney Disease Progression and Cardiovascular Outcome in Patients With Diabetic Nephropathy: A Post Hoc Analysis of the RENAAL (Reduction of End Points in Non-Insulin-Dependent Diabetes With the Angiotensin II Antagonist Losartan) St
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Bicarbonates; Biphenyl Compounds; Diabetes Mel | 2015 |
Serum bicarbonate and long-term outcomes in CKD.
Topics: Bicarbonates; Biomarkers; Cause of Death; Disease Progression; Female; Follow-Up Studies; Glomerular | 2010 |
Higher serum bicarbonate levels within the normal range are associated with better survival and renal outcomes in African Americans.
Topics: Adult; Aged; Antihypertensive Agents; Bicarbonates; Biomarkers; Black or African American; Chronic D | 2011 |
47 other studies available for hydrogen carbonate and Disease Exacerbation
| Article | Year |
|---|---|
Lower bicarbonate level is associated with CKD progression and all-cause mortality: a propensity score matching analysis.
Topics: Acidosis; Adult; Aged; Aged, 80 and over; Bicarbonates; Cause of Death; Creatinine; Disease Progress | 2022 |
Is bicarbonate therapy effective in preventing CKD progression?
Topics: Bicarbonates; Disease Progression; Female; Humans; Kidney Failure, Chronic; Male; Renal Insufficienc | 2022 |
Longitudinal Associations between Low Serum Bicarbonate and Linear Growth in Children with CKD.
Topics: Acidosis; Alkalies; Bicarbonates; Child; Disease Progression; Humans; Prospective Studies; Renal Ins | 2022 |
Alpha-methyltyrosine reduces the acute cardiovascular and behavioral sequelae in a murine model of traumatic brain injury.
Topics: alpha-Methyltyrosine; Animals; Bicarbonates; Brain Injuries, Traumatic; Catecholamines; Chlorides; D | 2023 |
Acidity promotes tumour progression by altering macrophage phenotype in prostate cancer.
Topics: Animals; Bicarbonates; Cell Line, Tumor; Computer Simulation; Cytokines; Disease Progression; Extrac | 2019 |
Relationship of Serum Bicarbonate Levels with 1-Year Graft Function in Kidney Transplant Recipients in Switzerland.
Topics: Acidosis; Bicarbonates; Disease Progression; Female; Humans; Kidney Transplantation; Male; Middle Ag | 2019 |
Low Serum Bicarbonate and CKD Progression in Children.
Topics: Acidosis; Adolescent; Bicarbonates; Buffers; Child; Child, Preschool; Disease Progression; Female; F | 2020 |
Metabolic Acidosis and CKD Progression.
Topics: Acidosis; Ammonium Compounds; Animals; Bicarbonates; Citric Acid; Disease Progression; Humans; Hydro | 2021 |
Modulation of the Association of Hypobicarbonatemia and Incident Kidney Failure With Replacement Therapy by Venous pH: A Cohort Study.
Topics: Acid-Base Imbalance; Bicarbonates; Disease Progression; Female; Glomerular Filtration Rate; Humans; | 2021 |
Serum bicarbonate is associated with kidney outcomes in autosomal dominant polycystic kidney disease.
Topics: Bicarbonates; Disease Progression; Glomerular Filtration Rate; Humans; Kidney; Polycystic Kidney, Au | 2021 |
Association of Pre-ESRD Serum Bicarbonate with Post-ESRD Mortality in Patients with Incident ESRD.
Topics: Aged; Bicarbonates; Disease Progression; Female; Humans; Kidney Failure, Chronic; Male; Middle Aged; | 2021 |
Metabolic acidosis is associated with increased risk of adverse kidney outcomes and mortality in patients with non-dialysis dependent chronic kidney disease: an observational cohort study.
Topics: Acidosis; Aged; Bicarbonates; Disease Progression; Female; Glomerular Filtration Rate; Humans; Incid | 2021 |
Metabolic acidosis is common and associates with disease progression in children with chronic kidney disease.
Topics: Acidosis; Adolescent; Bicarbonates; Child; Disease Progression; Female; Follow-Up Studies; Glomerula | 2017 |
Diagnosis and Treatment of Metabolic Acidosis in Patients with Chronic Kidney Disease - Position Statement of the Working Group of the Polish Society of Nephrology.
Topics: Acidosis; Bicarbonates; Disease Progression; Humans; Nephrology; Poland; Renal Insufficiency, Chroni | 2018 |
Are low levels of serum bicarbonate associated with risk of progressing to impaired fasting glucose/diabetes? A single-centre prospective cohort study in Beijing, China.
Topics: Adult; Bicarbonates; China; Diabetes Mellitus, Type 2; Disease Progression; Female; Glucose Toleranc | 2018 |
Association between serum Na-Cl level and renal function decline in chronic kidney disease: results from the chronic kidney disease Japan cohort (CKD-JAC) study.
Topics: Acidosis; Aged; Anemia; Bicarbonates; Biomarkers; Disease Progression; Down-Regulation; Female; Glom | 2019 |
Elevated serum anion gap in adults with moderate chronic kidney disease increases risk for progression to end-stage renal disease.
Topics: Acid-Base Equilibrium; Adult; Aged; Bicarbonates; Biomarkers; Cross-Sectional Studies; Disease Progr | 2019 |
Association of serum bicarbonate with risk of renal and cardiovascular outcomes in CKD: a report from the Chronic Renal Insufficiency Cohort (CRIC) study.
Topics: Adult; Aged; Bicarbonates; Cardiovascular Diseases; Cohort Studies; Disease Progression; Female; Hum | 2013 |
Dietary acid intake and kidney disease progression in the elderly.
Topics: Acids; Aged; Bicarbonates; Diet, Protein-Restricted; Dietary Proteins; Disease Progression; Disease- | 2014 |
Serum bicarbonate concentrations and kidney disease progression in community-living elders: the Health, Aging, and Body Composition (Health ABC) Study.
Topics: Acid-Base Imbalance; Aged; Albumins; Bicarbonates; Creatinine; Disease Progression; Female; Follow-U | 2014 |
Low serum bicarbonate and kidney function decline: the Multi-Ethnic Study of Atherosclerosis (MESA).
Topics: Acidosis; Aged; Albuminuria; Atherosclerosis; Bicarbonates; Cohort Studies; Creatinine; Cystatin C; | 2014 |
Prevalence of and risk factors for reduced serum bicarbonate in chronic kidney disease.
Topics: Acidosis; Adult; Aged; Bicarbonates; Biomarkers; Cross-Sectional Studies; Disease Progression; Down- | 2014 |
Warburg's effect on solid tumors.
Topics: Acidosis, Lactic; Acute Kidney Injury; Administration, Intravenous; Aged; Bicarbonates; Disease Prog | 2014 |
Presence of early CKD-related metabolic complications predict progression of stage 3 CKD: a case-controlled study.
Topics: Acidosis; Aged; Aged, 80 and over; Anemia; Bicarbonates; Calcium; Case-Control Studies; Creatine; Di | 2014 |
Persistent high serum bicarbonate and the risk of heart failure in patients with chronic kidney disease (CKD): A report from the Chronic Renal Insufficiency Cohort (CRIC) study.
Topics: Bicarbonates; Disease Progression; Diuretics; Female; Glomerular Filtration Rate; Heart Failure; Hum | 2015 |
The effect of lanthanum carbonate on metabolic acidosis in patients with chronic kidney disease stage IV, V and V-D.
Topics: Acidosis; Bicarbonates; Canada; Chelating Agents; Disease Progression; Drug Monitoring; Female; Huma | 2015 |
Derivation and Validation of Predictive Factors for Clinical Deterioration after Admission in Emergency Department Patients Presenting with Abnormal Vital Signs Without Shock.
Topics: Aged; Bicarbonates; Chronic Disease; Disease Progression; Emergency Service, Hospital; Health Status | 2015 |
Serum Bicarbonate in Acute Heart Failure: Relationship to Treatment Strategies and Clinical Outcomes.
Topics: Acute Disease; Aged; Bicarbonates; Biomarkers; Chi-Square Distribution; Disease Progression; Diureti | 2016 |
Higher net acid excretion is associated with a lower risk of kidney disease progression in patients with diabetes.
Topics: Acidosis; Acids; Aged; Ammonium Compounds; Bicarbonates; Biomarkers; Blood Urea Nitrogen; Diabetes M | 2017 |
[Metabolic acidosis in chronic kidney disease].
Topics: Acidosis; Bicarbonates; Disease Progression; Humans; Renal Dialysis; Renal Insufficiency, Chronic; S | 2016 |
Insulin resistance and beta cell function as prognostic indicator in multi-organ dysfunction syndrome.
Topics: Adolescent; Adult; Aged; APACHE; Bicarbonates; Blood Glucose; Critical Illness; Disease Progression; | 2009 |
Serum bicarbonate levels and the progression of kidney disease: a cohort study.
Topics: Bicarbonates; Cohort Studies; Disease Progression; Female; Humans; Kidney Diseases; Male; Middle Age | 2009 |
Lipopolysaccharide directly alters renal tubule transport through distinct TLR4-dependent pathways in basolateral and apical membranes.
Topics: Amiloride; Animals; Bicarbonates; Butadienes; Disease Progression; Endotoxemia; Escherichia coli Inf | 2009 |
Potential benefits of alkali therapy to prevent GFR loss: time for a palatable 'solution' for the management of CKD.
Topics: Acid-Base Equilibrium; Acidosis; Administration, Oral; Aldosterone; Animals; Bicarbonates; Chronic D | 2010 |
Galanin, a potent inhibitor of pancreatic bicarbonate secretion, is involved in the induction and progression of cerulein-induced experimental acute pancreatitis.
Topics: Acute Disease; Animals; Bicarbonates; Ceruletide; Disease Progression; Galanin; Mice; Pancreatitis | 2011 |
Dual role of CO2/HCO3(-) buffer in the regulation of intracellular pH of three-dimensional tumor growths.
Topics: 4,4'-Diisothiocyanostilbene-2,2'-Disulfonic Acid; Bicarbonates; Biological Transport; Buffers; Carbo | 2011 |
Clinical profile of distal renal tubular acidosis.
Topics: Acid-Base Equilibrium; Acidosis, Renal Tubular; Adolescent; Adult; Age Factors; Aged; Bicarbonates; | 2011 |
Correlation of cerebral spinal fluid pH and HCO3- with disease progression in ALS.
Topics: Acid-Base Equilibrium; Adult; Aged; Amyotrophic Lateral Sclerosis; Bicarbonates; Biomarkers; Cell De | 2011 |
Relationship between serum phosphorus and the progression of advanced chronic kidney disease.
Topics: Aged; Bicarbonates; Biomarkers; Calcitriol; Calcium; Chelating Agents; Chronic Disease; Confounding | 2011 |
Abnormal duodenal [HCO3-] following secretin stimulation develops sooner than endocrine insufficiency in minimal change chronic pancreatitis.
Topics: Adult; Bicarbonates; Chi-Square Distribution; Disease Progression; Duodenum; Endosonography; Exocrin | 2012 |
Acid-base balance of cats with chronic renal failure: effect of deterioration in renal function.
Topics: Acidosis; Animals; Bicarbonates; Cat Diseases; Cats; Creatinine; Disease Progression; Hydrogen-Ion C | 2003 |
The relationship of plasma glutamine to ammonium and of glycine to acid-base balance in propionic acidaemia.
Topics: Acid-Base Equilibrium; Amino Acid Metabolism, Inborn Errors; Bicarbonates; Biomarkers; Diet, Protein | 2003 |
Calcium citrate ameliorates the progression of chronic renal injury.
Topics: Alkalies; Animals; Bicarbonates; Calcium Citrate; Captopril; Cell Division; Disease Progression; Dru | 2004 |
Treatment of severe pediatric ethylene glycol intoxication without hemodialysis.
Topics: Acidosis; Adolescent; Antidotes; Bicarbonates; Child; Creatine; Disease Progression; Ethylene Glycol | 2004 |
Risk factors of renal failure progression two years prior to dialysis.
Topics: Anemia; Bicarbonates; Blood Proteins; Calcium; Cholesterol; Creatinine; Diabetic Nephropathies; Dise | 1999 |
Whole gut washout ameliorates the progression of acute experimental pancreatitis.
Topics: Acute Disease; Alanine Transaminase; Amylases; Animals; Bicarbonates; Blood Glucose; Calcium; Diseas | 2000 |
Clinical characteristics of non-immune-mediated, idiopathic type 1 (type 1B) diabetes mellitus in Japanese children and adolescents.
Topics: Adolescent; Age of Onset; Bicarbonates; Blood Glucose; C-Peptide; Child; Diabetes Mellitus, Type 1; | 2002 |